Pharming Group PHARM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
-
Pharming Group to participate in September investor conferences
-
Pharming Group reports second quarter and first half 2024 financial results and provides business update
-
Pharming Group to report second quarter and first half 2024 financial results on August 1
Trading Information
- Previous Close Price
- €0.71
- Day Range
- €0.71–0.78
- 52-Week Range
- €0.65–1.23
- Bid/Ask
- €0.77 / €0.78
- Market Cap
- €528.44 Mil
- Volume/Avg
- 15.6 Mil / 3.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.30
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 382
- Website
- https://www.pharming.com
Comparables
Valuation
|
Metric
|
PHARM
|
QURE
|
PHVS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.56 | 2.55 | 2.81 |
Price/Sales | 2.30 | 8.83 | — |
Price/Cash Flow | 98.52 | — | — |
Price/Earnings
PHARM
QURE
PHVS
Financial Strength
|
Metric
|
PHARM
|
QURE
|
PHVS
|
|---|---|---|---|
Quick Ratio | 2.65 | 6.61 | 18.14 |
Current Ratio | 3.39 | 7.36 | 18.45 |
Interest Coverage | −2.21 | −3.84 | — |
Quick Ratio
PHARM
QURE
PHVS
Profitability
|
Metric
|
PHARM
|
QURE
|
PHVS
|
|---|---|---|---|
Return on Assets (Normalized) | −4.16% | −31.33% | −35.77% |
Return on Equity (Normalized) | −8.62% | −121.03% | −37.92% |
Return on Invested Capital (Normalized) | −4.69% | −66.72% | −39.33% |
Return on Assets
PHARM
QURE
PHVS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Cxnvbrmcc | Wrjwn | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jzqwhcq | Cdfdwt | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pcfphmjd | Rslsnm | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xxbmpzcs | Qzlgf | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Rhhkgwy | Fdc | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Nsttqbrk | Rqlc | $28.1 Bil | |||
| Moderna Inc
MRNA
| Cflqzxxt | Ncln | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Hbjmcyfs | Bvct | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tqsvwkxsp | Jfsgm | $13.4 Bil | |||
| Incyte Corp
INCY
| Kpsbckmw | Fsypph | $12.7 Bil |
United States